Recordati and Amarin Partner to Expand Heart Drug Vazkepa Across 59 Countries

Recordati’s Agreement with Amarin

Image Credits: Fierce Pharma

Announcement

Recordati, an international pharmaceutical company, signed a license and supply agreement with Amarin, a company known for the treatment of cardiovascular diseases. The agreement’s purpose is to present a marketed cardiovascular medicine, Vazkepa (icosapent ethyl), in 59 countries, with a focus on Europe. This agreement between the two leading companies will spread awareness of new medicine (treatment) and fuel the healthcare market.

About Vazkepa

Vazkepa tends to minimize the risk of cardiovascular events in adult patients with statins at the highest risk of cardiovascular events, with triglycerides and diabetes or other cardiovascular diseases. Vazkepa received approval in 2021in the UK and EU and 2022 in Switzerland regarding its REDUCE-IT study. The study was a phase 3 cardiovascular outcomes trial (CVOT), treated in 8000 patients with positive clinical and statistical results in Major adverse cardiovascular events (MACE). Vazkepa is the only treatment option that has shown a positive result in reducing cardiovascular risk in statin-treated individuals with high triglycerides in cardiovascular trials. It has been introduced as a therapeutic option with scientific statements and various treatment guidelines due to its advanced clinical data package.

Vazkepa has patent protection in Europe till 2039. As Vazkepa is marketed in 11 European countries with a net sale of €12 million in 2024, and is expected to increase revenue by €40 million by 2027, and will be EBITDA positive by 2026.

Agreement

Under the agreement’s terms and conditions, Recordati will pay an upfront cash payment of US$25 million to Amarin. Recordati will receive finished products from Amarin. Amarin will be liable to receive royalties for the supplied products and commercial milestones total of US$150 million, if Vazkepa’s annual revenue in territories increases to sales starting from € 100 million.

Views and Statements

Chief Executive Officer, Recordati, Rob Koremans, said, “The company is happy with the agreement with Amarin for Vazkepa that demonstrates deep expertise in the cardiovascular field and the company’s commitment towards building a strong foundation in our specialty & primary care business.”

EVP, Specialty & primary care, Alberto Martinez said, “Vazkepa is well suited for our portfolio. It is supported by growing medical advocacy and strong science, and has been granted an extended patent right in Europe.”

President & CEO of Amarin, Aaron Berg, said, “Recordati is a well-established, excellent partner is focusing on expanding marketing opportunities for Vazkepa. The company is confident about Recordati’s capability to continue the growth and impact in patient care with the Vazkepa solution in Europe.”